Weitiao No.3(微调3号方)enhances the efficacy of anti-programmed cell death protein-1 immunotherapy by modulating the intestinal microbiota in an orthotopic model of gastric cancer mice

OBJECTIVE:To explore the effects of Weitiao No.3(微调3号方,WD-3)on anti-programmed cell death protein-1(PD-1)immunotherapy in gastric cancer(GC).METHODS:The intestinal microbiota was analyzed by 16S rDNA sequencing of fecal samples from three groups:healthy people(Health),GC patients(GC),and WD-3-treated GC patients(WD-3).Next,we established an orthotopic model of GC mice,which were treated with anti-PD-1,WD-3,or an inoculation of intestinal bacteria.Immune markers CD3,CD4,CD8,and forkhead box protein P3(FOXP3),and the cell proliferation marker Ki67,were evaluated by immunohistochemistry.Cell apoptosis in GC tumors was assessed by terminaldeoxynucleotidyl-transferase-mediated deoxyuridine triphosphate nick end labeling staining.Enzyme-linked immunosorbent assays(ELISAs)were performed to analyze the serum levels of the following cytokines in GC mice:tumor necrosis factor(TNF)-α,interleukin(IL)-2,IL-6,IL-10,interferon(IFN)-γ,and transforming growth factor(TGF)-β.RESULTS:Sequencing data showed that there were significant differences in the composition of the gut microbial community among the three human groups.The gut bacteria in the three groups mainly comprised the phyla Firmicutes,Proteobacteria,Bacteroidetes,and Actinobacteria.At the genus level,the relative abundances of Bifidobacterium and Coprococcus showed significant decreases in the GC group,and an obvious increase in the WD-3 group,compared with the Health group.Interestingly,the relative abundance of Saccharopolyspora was only detected in the WD-3 group.The results of in vivo experiments in GC mice showed that WD-3 or anti-PD-1 treatment increased the levels of CD3+,CD4+,and CD8+T cells,but decreased the levels of FOXP3+regulatory T cells.Furthermore,WD-3 or PD-1 antibody treatment inhibited proliferation and promoted apoptosis of GC tumor cells.ELISA analysis showed that WD-3 or PD-1 antibody treatment facilitated TNF-α,IL-2,and IFN-γexpression,while suppressing IL-6,IL-10,and TGF-βexpression.Combination therapy with WD-3 and anti-PD-1 intensified all of these effects.CONCLUSION:WD-3 enhanced the immunotherapeutic efficacy of anti-PD-1 by modulating the intestinal microbiota in an orthotopic model of GC mice.

中药微调五号方联合生物反应调节剂对肾癌患者肿瘤标志物及生活质量的影响

目的:分析中药微调五号方联合生物反应调节剂重组人白介素-2(IL-2)、重组人干扰素α2b(IFN-α2b)对肾癌患者肿瘤标志物及生活质量的影响。方法:将50例肾癌患者用双盲法分为对照组(IFN-α2b、IL-2皮下注射)、观察组(加用中药微调五号)。统计客观疗效中缓解率、治疗前后肿瘤标志物水平、T细胞亚群主要指标变化,记录QLQ-C30生命质量、生活质量卡氏评分(KPS)分值,记录Ⅲ度、Ⅵ度不良反应发生率。结果:治疗后,观察组缓解率(24.00%)与对照组无显著差异,P>0.05;观察组NSE低于对照组;观察组CD_4^+升高,CD_8^+下降,CD_4^+/CD_8^+升高,均优于对照组;观察组除认知功能分值外QLQ-C30其它指标分值均高于对照组;观察组卡氏评分高于对照组;观察组Ⅲ度、Ⅵ度不良反应发生率(4.00%)低于对照组。均P<0.05。结论:中药微调五号联合生物反应调节剂能显著抑制部分肿瘤标志物,提高患者免疫力,改善生命质量和生活质量,减少严重不良反应,值得推广。

点按微调手法治疗神经根型颈椎病

目的:观察坐位定点点按微调手法为主的推拿方法治疗神经根型颈椎病的疗效。方法:将68例患者随机分为两组,治疗组34例,采用手法放松后坐位定点点按微调手法治疗;对照组34例,采用传统推拿治疗。结果:治疗组、对照组总有效率分别为97.1%和88.2%。治愈患者第1疗程比较分别为36.4%和23.1%;第2疗程为54.5%和30.8%。经统计学处理,两组疗效差异有统计学意义(P<0.05)。结论:坐位定点点按微调手法为主的推拿方法治疗神经根型颈椎病疗效明显优于传统的推拿方法,且安全易被接受。

微调三号方合化学疗法对Ⅳ期胃癌患者生存质量的影响

目的观察微调三号方联合XELOX方案(希罗达+奥沙利铂)对Ⅳ期胃癌患者生存质量的疗效。方法将51例Ⅳ期胃癌患者随机分为治疗组和对照组,治疗组26例采用微调三号方联合XELOX方案化学治疗,对照组25例单纯接受XELOX方案化学治疗。采用欧洲癌症研究与治疗组织生命质量核心量表(European organization for research and treatment of cancer quality of life core questionnaire 30,EORTCQLQ-C30)及体力状况Karnofsky评分标准,进行两组生存质量的对照观察。结果治疗组在改善Ⅳ期胃癌患者EORTC QLQ-C30量表的乏力、恶心呕吐、失眠、食欲丧失、腹泻、总体健康状况及提高Karnofsky评分方面显著优于对照组(P<0.05,或P<0.01)。结论微调三号方联合XELOX方案治疗能够提高Ⅳ期胃癌患者的生存质量。

中药赵氏微调三号治疗大肠癌临床与实验研究

目的:观察中药赵氏微调三号治疗大肠癌的临床及实验疗效。方法:大肠癌患者口服中药赵氏微调三号6个月以上,观察临床主要症状、生活质量、客观疗效、生存率等指标。观察中药赵氏微调三号对移植性肉瘤的抑瘤作用、对实验动物细胞因子的影响、对人大肠癌HT-29细胞和大肠癌LOVO细胞的抑制及诱导凋亡作用。结果:赵氏微调三号可以改善大肠癌患者的临床症状(总有效率为89.52%),提高生活质量(P<0.05),稳定肿瘤(临床获益率86.67%),延长生命(3年生存率为49.52%)。实验研究显示中药赵氏微调三号的抑瘤率为29.68%,能显著提高细胞因子白介素-2(IL-2)、白介素-4(IL-4)、γ-干扰素(IFN-γ)的水平,可使HT-29、LOVO大肠癌细胞发生凋亡。结论:中药赵氏微调三号治疗大肠癌,可以改善患者主要症状,提高生活质量,抑制肿瘤、促使大肠癌细胞凋亡,延长患者生存期。